| Literature DB >> 34073260 |
Joaquim Calvo-Lerma1, Mieke Boon2, Jessie Hulst3, Carla Colombo4, Inês Asseiceira5, María Garriga6, Etna Masip1, Ine Claes2, Anna Bulfamante4, Hettie M Janssens7,8, Maria Roca1, Saioa Vicente6, Victoria Fornés9, Laura Zazzeron4, Bo van Schijndel7,8, Sandra Woodcock7,8, Luisa Pereira5, Kris de Boeck2, Carmen Ribes-Koninckx1.
Abstract
Cystic Fibrosis (CF) is a life-long genetic disease, causing increased energy needs and a healthy diet with a specific nutrient distribution. Nutritional status is an indicator of disease prognosis and survival. This study aimed at assessing the effectiveness of a self-management mobile app in supporting patients with CF to achieve the dietary goals set by the CF nutrition guidelines. A clinical trial was conducted in pancreatic insufficient children with CF, followed in six European CF centres, where the self-management app developed within the MyCyFAPP project was used for six months. To assess secondary outcomes, three-day food records were compiled in the app at baseline and after 3 and 6 months of use. Eighty-four subjects (mean 7.8 years old) were enrolled. Compared to baseline, macronutrient distribution better approximated the guidelines, with protein and lipid increasing by 1.0 and 2.1% of the total energy intake, respectively, by the end of the study. Consequently, carbohydrate intake of the total energy intake decreased significantly (-2.9%), along with simple carbohydrate intake (-2.4%). Regarding food groups, a decrease in ultra-processed foods was documented, with a concomitant increase in meat and dairy. The use of a self-management mobile app to self-monitor dietary intake could become a useful tool to achieve adherence to guideline recommendations, if validated during a longer period of time or against a control group.Entities:
Keywords: cystic fibrosis; diet; dietary habits; food groups; m-health; nutrients; nutrition; self-management
Year: 2021 PMID: 34073260 PMCID: PMC8229611 DOI: 10.3390/nu13061801
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Change in daily energy intake along the three study visits (v1, baseline; v2, month 3; v3, month 6) in the study cohort (n = 84). (a) expressed as median kcal/day; (b) expressed as deviation% from minimum recommended daily energy intake (110% with respect to age and gender-matched populations, represented by horizontal dotted line) [3].
Figure 2Changes in macronutrient intake during the 6-months period of use of the self-management mobile app in the study cohort (n = 84): (a) protein, (b) carbohydrate and (c) lipids. Grey areas represent the range of the recommended intake according to Turk et al. (2016) [3]. According to the WHO guidelines, simple CH (sugar) intake should not be higher than 5% energy intake, and SFA should not exceed 10%. * statistically significant change (p < 0.05) between visit in month 0 (v1) and month 6 (v3). Original to this manuscript).
Change in macronutrient contribution (% of total daily energy intake) after the 6-month intervention with the self-management mobile app.
| % of Total Energy Intake | Difference from v1 to v3 | Odds Ratio, | 95% Confidence Interval |
|---|---|---|---|
| % Protein intake | +1.0% | 1.09, | (1.03, 1.15) |
| % Lipid intake | +2.0% | 1.09, | (1.01, 1.18) |
| % SFA intake | −0.4% | 0.97, | (0.90, 1.04) |
| % MUFA intake | +0.6% | 1.05, | (0.96, 1.14) |
| % PUFA intake | +0.6% | 1.09, | (0.95, 1.25) |
| % CH intake | −2.5% | 0.88, | (0.81, 0.95) |
| % Simple CH intake | −2.4% | 0.81, | (0.73, 0.89) |
| % Complex CH intake | +1.0% | 1.03, | (1.01, 1.07) |
SFA: saturated fatty acids; MUFA; monounsaturated fatty acids; PUFA; polyunsaturated fatty acids; CH: carbohydrates.
Figure 3Evolution of macronutrient intake during the 6-months period of use of the self-management mobile app in the six participating European centres: (a) protein, (b) carbohydrates and (c) lipid. Grey areas represent the range of the recommended intake according to Turck et al. (2016) [3].
Figure 4Relative contribution of food groups to total daily energy intake at study baseline (v1) and after the intervention (v3) of the clinical trial in the six European participating centres. Original to this manuscript.